AORT
Artivion, Inc.
NYSE · Healthcare · Medical - Devices · US
$25.51
−0.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 471.5M | 441.3M | 388.5M | 354.0M | 313.8M |
| Cost of Revenue | 175.4M | 170.9M | 139.8M | 124.8M | 111.3M |
| Gross Profit | 296.1M | 270.5M | 248.8M | 229.2M | 202.5M |
| Operating Expenses | |||||
| R&D Expense | 35.1M | 31.0M | 28.5M | 28.7M | 38.9M |
| SG&A Expense | 243.1M | 212.7M | 192.4M | 209.0M | 157.4M |
| General & Admin Expense | 79.8M | — | 190.7M | — | — |
| Selling & Marketing Expense | — | — | 1.7M | — | — |
| Other Expenses | (900.0K) | — | (10.9M) | (14.3M) | — |
| Total Operating Expenses | 277.3M | 243.7M | 209.9M | 223.4M | 196.3M |
| Cost and Expenses | 452.6M | 414.6M | 349.7M | 348.3M | 307.6M |
| Operating Income (EBIT) | 18.8M | 26.7M | 38.9M | 5.7M | 6.2M |
| Non-Operating | |||||
| Interest Income | 1.1M | 763.0K | 1.5M | 1.1M | 147.0K |
| Interest Expense | 24.3M | 26.6M | 34.3M | 25.3M | 18.2M |
| Net Interest Income | (23.1M) | (25.8M) | (32.8M) | (24.2M) | (18.1M) |
| Other Non-Op Income/Expense | (16.6M) | (12.0M) | (46.4M) | (27.3M) | (21.2M) |
| Non-Operating Income (excl Interest) | (7.7M) | (14.6M) | 12.1M | 2.0M | 3.0M |
| EBT (Pre-Tax Income) | 2.2M | 14.8M | (7.5M) | (21.6M) | (15.0M) |
| Income Tax Expense | 5.4M | 5.0M | 5.8M | 9.1M | 4.2M |
| Bottom Line | |||||
| Net Income | (3.2M) | 9.8M | (13.4M) | (30.7M) | (19.2M) |
| Earnings from Cont. Ops | (3.2M) | 9.8M | (13.4M) | (30.7M) | (19.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.2M) | 9.8M | (13.3M) | (30.6M) | (19.1M) |
| Per Share | |||||
| Basic EPS | ($0.06) | $0.22 | ($0.32) | ($0.75) | ($0.48) |
| Diluted EPS | ($0.07) | $0.21 | ($0.32) | ($0.75) | ($0.48) |
| Revenue Per Share | $9.71 | $9.73 | $9.32 | $8.69 | $7.84 |
| Shares | |||||
| Basic Shares Outstanding | 48.5M | 45.3M | 41.7M | 40.7M | 40.0M |
| Diluted Shares Outstanding | 48.5M | 47.2M | 41.7M | 40.7M | 40.0M |
| Profitability Metrics | |||||
| EBITDA | 57.4M | 63.8M | 51.0M | 26.8M | 25.7M |
| D&A | 30.9M | 22.5M | 24.2M | 23.1M | 22.4M |
| EBIT | 26.5M | 41.4M | 26.8M | 3.7M | 3.2M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026